Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase
View Patent ↗Optionally O-substituted glycero-phosphoinositol derivatives, their analogues and their salts wherein the substitutents: R′1, R′2, R2, R3, R4, R5, R6 have the described meaning, their synthesis and their pharmacological effect as modulators of the activation or over-stimulation of cPLA2.
1. Method of treatment of inflammation comprising the administration, to a patient in need thereof, of a compound of formula (I):
wherein:
R1′, R2′, R2, R3, R4, R5, R6 is each, independently,
(a) H; or
(b) C(O)A, an acylic mono-carboxylic acid or di-carboxylic acid, where A is a radical selected from the group consisting of
(i) a saturated or unsaturated, straight or branched, alkyl radical having from 1 to no more than 8 carbon atoms and from 0 to no more than 4 double bonds;
(ii) a mono- or polycyclic alkyl or alkenyl radical and
(iii) an aryl, arylalkyl or heterocyclic radical having one or more heteroatoms;
wherein said radical is unsubstituted or substituted with one or more groups selected from the group consisting of keto, hydroxyl, acylamidic, halogen, mercapto, alkylthio or alkyldithio, —COOH, wherein the —COOH is salified to form a —COOM salt, or unsalified, and
wherein M is the cation of a pharmaceutically acceptable inorganic element or a cation of a pharmacologically acceptable organic base, both having a valence n+, wherein n is 1 or 2 or 3, and;
X and Y are O.
2. A method according to claim 1 , wherein M is:
(a) a biologically acceptable inorganic cation; or,
(b) a biologically acceptable organic cation having valence n+ wherein n is 1, 2, or 3.
3. A method according to claim 1 , wherein:
(a) A is selected from the group consisting of
(i) a mono- or polycyclic alkyl or alkenyl radical having 5 to 30 carbon atoms; and,
(ii) an aryl radical, arylalkyl radical, or heterocycle radical having one or more heteroatoms and 4 to 15 carbon atoms, said one or more heteroatoms selected from the group consisting of N, O, and S.
4. A method according to claim 2 , wherein M is:
(a) a biologically acceptable inorganic cation selected from the group consisting of chromium, copper, alkaline elements, earth alkaline, Zn and Fe; or,
(b) a cation of a biologically acceptable organic base selected from the group consisting of mono-, di-, tri-, and tetra-alkylammonium; N-(2-hydroxyethyl)dimethylammonium; choline cation; and an aminoacid cation selected from the group consisting of lysine, arginine, carnosine, dipeptides, tripeptides, and cations of xanthine base.
5. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being associated with overstimulation of growth factors EGF or NGF and/or NK-1 receptor and/or of receptors coupled with G proteins that activate cPLA2, such as ATP receptors and/or bombesin receptors.
6. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being cardiogenic or septic shock or viral or bacterial infection.
7. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being a pathology of the respiratory apparatus resulting from acute pulmonary damage in an adult, a child, or a newborn infant or a chronic obstructive alteration.
8. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being a dermatologic pathology selected from the group consisting of psoriasis, seborrhoic dermatitis, atopic dermatitis, and skin disreactivity from oxidative stress following UVB damage; or an ophthalmic pathology selected from the group consisting of glaucoma and conjunctivitis.
9. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being a tumour pathology of the prostate or kidney.
10. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being selected from the group consisting of alterations of gingival tissue due to a bacterial infection, and mucosal damage in intestinal ischaemia.
11. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being an articular alteration selected from the group consisting of arthritis and arthrosis.
12. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being selected from the group consisting of migraine, headache, pain, and hyperalgesia.
13. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being selected from the group consisting of a cardiac disorder and cardiovascular disease associated with vascular remodelling.
14. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being a pathology of the peripheral nervous system; a toxic-dismetabolic neuropathy; a pathology of the central nervous system selected from the group consisting of Alzheimer's disease, schizophrenia, and depression; a pathology caused by iatrogenic damage; a pathology caused by toxic agents such as cocaine; or a cutaneous disorder or alteration associated with the sphyngomielin cycle selected from the group consisting of the Hermansky-Pudlak syndrome and the Nieman-Pick syndrome.
15. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being associated with damage to a vessel/nervous-system barrier such as the blood brain barrier, including pathologies associated with vessel/nervous-system barrier damage selected from the group consisting of neuronal edema, stroke, cerebral edema and hemorrhage, and transient ischemic attack.
16. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being related to food intake disorders selected from the group consisting of bulimia, anorexia, cachexia, and obesity.
17. A method according to claim 1 , wherein the inflammation is associated with a pathology mediated by activation or overstimulation of cPLA2, said pathology being a dis-metabolic pathology selected from the group consisting of diabetes and pancreatitis.
18. A method according to claim 1 , wherein the compound of formula (I) is administered as an active ingredient in a veterinary pharmaceutical composition.
19. A method according to claim 1 , wherein the compound of formula (I) is administered to the patient in one or more cycles of treatment, each treatment cycle comprising administering a dose of the compound of formula (I) included between 0.1 to 100 mg/kg for 3-90 days.